1. Introduction

Customs seizure of investigational therapies arises when customs authorities detain, confiscate, or initiate proceedings against medicines that have not yet received full marketing approval. These products may include experimental cancer drugs, gene therapies, biologics, cell-based therapies, orphan drugs, and medicines imported for clinical trials or compassionate use.

The central legal conflict is between two legitimate interests:

Regulatory and public-health interests: preventing unsafe, counterfeit, unlicensed, or improperly imported medicines from entering the country.

Patient rights and interests: protecting life, health, dignity, access to lawful treatment, informed consent, and timely decisions where a patient has few or no therapeutic alternatives.

An investigational therapy is not automatically illegal merely because it lacks full marketing approval. However, a prescription, a doctor's recommendation, or a patient's urgent medical condition does not automatically legalise its importation either. The applicable licensing, clinical-trial, and customs requirements must be examined.

This discussion focuses primarily on Indian law, with comparative United States authorities where they illuminate the relationship between customs enforcement and access to experimental medicines.

2. Legal framework in India

A. Drugs and Cosmetics Act, 1940

The principal legislation governing the importation of medicines is the Drugs and Cosmetics Act, 1940.

Section 10 restricts the import of specified categories of drugs, including certain drugs imported contrary to statutory requirements or applicable licensing conditions.

Section 11 expressly connects customs enforcement with the regulation of prohibited drug imports. It permits customs authorities to detain packages suspected of containing prohibited drugs and requires the detention to be reported to the Drugs Controller, India; suspected products or samples may also be sent for laboratory examination.

CDSCO+1

The legal significance is that customs detention may be justified to establish whether a consignment complies with drug-import requirements. It does not mean that every investigational medicine must necessarily be destroyed or permanently confiscated.

B. Drugs and Cosmetics Rules, 1945

Rule 36 addresses the importation of small quantities of drugs for personal use, subject to prescribed conditions. Depending on the circumstances, a permit may be required where the medicine is not imported as part of bona fide passenger baggage.

Rules 38–40 address accompanying documentation and procedures for imported drugs, including sampling and detention where compliance is in doubt.

CDSCO+1

These provisions are important when a patient imports an experimental medicine personally rather than through a hospital, clinical-trial sponsor, or authorised importer.

Important limitation: the personal-use route is not a universal exemption for investigational medicines. The exact product, quantity, purpose, licensing position, and applicable restrictions must be checked.

C. New Drugs and Clinical Trials Rules, 2019

The New Drugs and Clinical Trials Rules, 2019 provide a more specialised framework for new drugs and clinical-trial-related imports.

Relevant issues include:

Whether the product is a new drug or investigational product under the rules.

Whether the importer holds the appropriate permission or licence.

Whether the import is for a clinical trial, a bioavailability or bioequivalence study, or examination, testing, or analysis.

Whether required records, storage conditions, and restrictions on use are satisfied.

Rules 68–72 include provisions governing relevant import licences, inspection, and suspension or cancellation. Rule 72 contemplates an opportunity to show cause and be heard before suspension or cancellation in the circumstances specified by the rule.

IndiaCode+1

The precise permission required depends on the product and the intended use. A clinical-trial import should not automatically be treated as equivalent to a personal compassionate-use import.

3. Patient rights when an investigational therapy is seized

A. Right to life and health

Article 21 of the Constitution of India protects life and personal liberty. Indian courts have interpreted this protection to include important aspects of access to medical care and the preservation of life.

Nevertheless, Article 21 does not automatically create a right to import or receive any experimental medicine regardless of regulatory restrictions. The patient's medical circumstances must be balanced against the statutory framework and legitimate public-health concerns.

B. Right to lawful and fair administrative action

A patient or importer affected by seizure may challenge the action where there is a credible basis to argue that it was:

Beyond the authority conferred by statute.

Based on an incorrect understanding of the medicine's regulatory status.

Taken without following a mandatory procedure.

Arbitrary, discriminatory, or inadequately justified.

Continued for an unreasonable period without appropriate examination or decision.

Where applicable, Article 14's guarantee against arbitrary state action and the procedural protections under the relevant legislation may support judicial review.

C. Right to seek urgent consideration

Time may be particularly important for investigational treatments. A biologic may require continuous refrigeration, or a patient may have a rapidly progressing disease. A prolonged detention can make a product unusable or eliminate the therapeutic opportunity altogether.

A patient may therefore request expedited consideration, preservation of the product under suitable storage conditions, prompt review by the competent drug regulator, and a reasoned decision.

These requests do not guarantee release. The authority must still determine whether release would be lawful and medically appropriate.

D. Right to information and representation

Depending on the statutory procedure and the nature of the action, the affected patient or importer may seek:

The detention or seizure order and its legal basis.

Identification of the medicine and the alleged import violation.

The status of testing, licensing verification, or regulatory referral.

An opportunity to submit prescriptions, medical opinions, permits, and supporting records.

A hearing or review where required by law.

The patient's rights are not necessarily identical to those of the importer or clinical-trial sponsor. A patient may need to act through an authorised importer, treating physician, hospital, or other legally appropriate representative.

4. Important case laws

The following decisions establish relevant principles concerning health, administrative legality, and customs seizure. They do not all concern investigational medicines directly; their relevance must be distinguished carefully.

Case 1: State of Punjab v. Mohinder Singh Chawla (1997)

Supreme Court of India · (1997) 2 SCC 83

Facts: The case concerned medical treatment and reimbursement of expenses incurred by a government employee who required specialised cardiac treatment.

Legal principle: The Supreme Court recognised that the right to health is integral to the right to life under Article 21. The case supports the proposition that medical needs cannot be treated as legally insignificant when government decisions affect access to treatment.

Indian Kanoon

Application to customs seizure: A patient may rely on the constitutional importance of health when requesting urgent and fair consideration of a detained medicine. However, the judgment does not establish a general constitutional entitlement to import an unapproved drug in breach of statutory requirements.

Case 2: Paschim Banga Khet Mazdoor Samity v. State of West Bengal (1996)

Supreme Court of India · (1996) 4 SCC 37

Facts: A seriously injured person was denied treatment at multiple government hospitals because of inadequate facilities.

Legal principle: The Court held that failure by government hospitals to provide timely emergency medical treatment in the circumstances violated Article 21. It emphasised the State's obligation to safeguard human life through an appropriate healthcare system.

Application to customs seizure: The judgment supports arguments for urgent coordination between customs officials, drug regulators, and medical institutions where a detention threatens a patient's life. Its direct holding concerns emergency healthcare, not the legality of importing investigational medicines.

Case 3: Benten v. Kessler (1992)

United States Supreme Court · 505 U.S. 1084 (1992)

Underlying district court decision: 799 F. Supp. 281 (E.D.N.Y. 1992)

This is a particularly relevant comparative authority because it involved the seizure of an unapproved medicine at customs.

Facts: Leona Benten attempted to import RU-486 (mifepristone) into the United States. Federal authorities seized the medicine under an import restriction. The district court ordered its return on the facts before it, finding a substantial basis for challenging the agency's procedure.

Justia Law

Supreme Court outcome: The Supreme Court denied an application to vacate the appellate stay of the district court's order. It did not decide the underlying constitutional claim that the seizure impermissibly burdened abortion rights.

Justia U.S. Supreme Court Center

Legal significance: The case illustrates three important propositions:

Customs seizure of an unapproved medicine can be challenged through judicial review.

Courts may examine whether an agency has followed the legally required procedures for its restrictions.

Urgency and the practical consequences of detention may be relevant to the relief sought.

Limitation: The district court's order was fact-specific, and the Supreme Court's decision did not establish a general right to recover unapproved medicines. The case is persuasive comparative authority, not binding law in India.

Case 4: B.P. Singhal v. Union of India (2010)

Supreme Court of India · (2010) 6 SCC 331

Legal principle: The Supreme Court examined constitutional limitations on the exercise of executive power, including the requirement that discretion not be exercised arbitrarily.

Application: Where a patient alleges that a medicine was detained through arbitrary or legally unsupported executive action, constitutional review may be relevant. However, this case did not concern pharmaceutical imports, and it does not displace the specific statutory powers of customs or drug regulators.

Case 5: Mohinder Singh Gill v. Chief Election Commissioner (1978)

Supreme Court of India · (1978) 1 SCC 405

Legal principle: An administrative order must ordinarily be assessed by reference to the reasons on which it was made; its validity cannot simply be repaired through new reasons supplied later in litigation.

Application: If an investigational therapy is detained on stated grounds, the legality of that action may be tested against the actual statutory basis and recorded reasons, subject to the applicable rules and recognised exceptions.

This is a general administrative-law principle rather than a pharmaceutical-seizure precedent.

Case 6: Parmanand Katara v. Union of India (1989)

Supreme Court of India · (1989) 4 SCC 286

Legal principle: The Court emphasised the importance of immediate medical assistance to preserve life, particularly in emergencies.

Application: Where detention of a therapy creates a serious and immediate medical risk, this principle may strengthen a request for urgent administrative attention. It does not, by itself, authorise customs officials to disregard statutory restrictions.

5. Comparative United States law: compassionate access

The United States provides a useful comparison because its law expressly regulates certain forms of access to investigational products outside ordinary clinical trials.

Under 21 U.S.C. § 360bbb and the FDA's expanded-access framework, qualifying patients may obtain investigational drugs through authorised procedures, including individual-patient pathways. Eligibility depends on factors such as disease severity, the availability of satisfactory alternatives, and the balance of potential benefits and risks.

U.S. Congress+2

The framework does not establish an unconditional right to experimental medicine. A manufacturer may also decline to supply a product.

The relevance to customs seizure is that lawful access depends on a coordinated regulatory pathway, not merely on the existence of a prescription or a compassionate-use request.

6. Legal remedies available in India

Where a patient's investigational therapy has been detained, the appropriate remedy will depend on the legal basis for detention and the urgency of the medical situation.

1. Request immediate review

Submit a written representation to the customs authority and the competent drug regulator. Explain the medical urgency, identify the product, and request expedited verification of the applicable import permission.

2. Request preservation of the medicine

For temperature-sensitive biologics, cell therapies, or other perishable products, request appropriate storage, maintenance of the cold chain, and documented handling while the matter is pending.

3. Seek administrative or judicial review

Depending on the order and statutory route, the affected party may pursue an available departmental remedy or seek relief under Article 226 before the appropriate High Court. Article 32 may be relevant where a genuine fundamental-rights violation warrants recourse to the Supreme Court.

4. Request urgent, tailored relief

Where the evidence establishes a genuine emergency, the applicant may seek expedited consideration, preservation of the product, or other legally permissible interim relief. Release should not be assumed where the medicine is prohibited or presents unresolved safety concerns.

7. Evidence that can strengthen a patient's case

A properly documented application should ordinarily address the following matters:

A physician's report should explain why delay matters medically rather than merely state that the therapy is desirable.

8. Balancing patient rights against customs enforcement

The legal analysis can be organised around five questions.

Is the medicine legally importable? Determine its regulatory classification and whether the relevant permissions or exemptions apply.

Was the seizure authorised? Identify the statutory provision, the grounds for detention, and compliance with the required procedure.

Is there a genuine medical emergency? Establish the patient's condition, the treatment window, and the consequences of delay.

Can the concern be addressed through a narrower measure? Consider expedited testing, regulatory consultation, appropriate storage, or another lawful solution rather than assuming that release or destruction is the only option.

What remedy is legally available? Consider departmental review, judicial review, interim relief, and any other remedy authorised by the applicable law.

The essential distinction is between a lawful precautionary detention and an unlawful or unnecessarily prolonged interference with access to treatment. The former may be necessary to protect patients; the latter may be open to challenge where the facts and law justify it.

9. Conclusion

Customs seizure of investigational therapies presents a difficult intersection of pharmaceutical regulation, constitutional rights, administrative law, and medical urgency.

In India, Sections 10 and 11 of the Drugs and Cosmetics Act, the Drugs and Cosmetics Rules, 1945, and the New Drugs and Clinical Trials Rules, 2019, provide the central regulatory framework. Constitutional decisions such as Paschim Banga Khet Mazdoor Samity and Mohinder Singh Chawla support the importance of protecting life and health, while Benten v. Kessler illustrates how the seizure of an unapproved medicine may raise questions of administrative legality and urgent judicial relief.

The governing principle is not that patient need automatically overrides customs law, nor that regulatory enforcement automatically overrides every patient interest. The legality of the detention, the applicable authorisation pathway, the evidence of medical urgency, and the availability of proportionate lawful remedies must be assessed together.

Scope note: This is a general legal research overview, not a determination of any particular seizure. The exact remedy depends on the medicine, the import documents, the seizure order, and the patient's circumstances. A current Indian statute-and-case-law check is advisable before filing proceedings.